

ENDOLUMINAL TREATMENT OF OBESITY

Matthew D. McCollough, M.D.

Fellow

University of Louisville

Division of Gastroenterology, Hepatology, and
Nutrition

- ▣ America spends as much as \$147 billion annually on the direct and indirect costs of obesity.

Why Care?

Health Risks Associated with Obesity

- ▣ Coronary artery disease
- ▣ Hypertension
- ▣ Type II diabetes mellitus
- ▣ Asthma
- ▣ Hypoventilation syndrome
- ▣ Obstructive sleep apnea
- ▣ GERD
- ▣ Esophagitis
- ▣ Fatty liver
- ▣ Cholelithiasis
- ▣ NASH
- ▣ Cirrhosis
- ▣ Stress urinary incontinence
- ▣ Venous stasis/superficial phlebitis
- ▣ DVT/PE
- ▣ Hernias (inguinal, ventral, umbilical, incisional)
- ▣ PCOS
- ▣ Cancer (colon, prostate, breast, uterine)
- ▣ Cellulitis, panniculitis, post-op wound infections
- ▣ DJD, OA
- ▣ Psuedotumor cerebri
- ▣ Depression

Objectives

- ▣ Review obesity related terms
- ▣ Revisit past and present surgical options
- ▣ Discuss endoluminal approaches to obesity


Body Mass Index (BMI)

$$\text{Wgt (kg)} / (\text{Ht(m)})^2$$

or

$$\text{lbs/in}^2 \times 703$$

WEIGHT FOR HEIGHT CHART **FOR MEN AND WOMEN FROM 18 YEARS AND OVER**




BMI	Classification
< 18.5	Underweight
< 16	Severe thinness
16 – 16.9	Moderate thinness
17 – 18.4	Mild thinness
18.5 – 24.9	Healthy weight
25.0 – 29.9	Overweight
30.0 - 34.9	Class I obesity
35.0 – 39.9	Class II obesity
40 – 49.9	Class III obesity (extreme or morbid)
>50	Class IV obesity (super morbid)

World Health Organization 2004

Obesity in Children

- ▣ Underweight = below 5th percentile
- ▣ Healthy weight – 5th to 85th percentile
- ▣ Overweight – 85th -95th percentile
- ▣ Obese – above 95th percentile





Terms

- ▣ Excessive Weight
 - ▣ Patient's weight – weight of an individual of same height with a BMI of 25
- ▣ Percentage of excess weight loss (%EWL)
 - $\text{Weight lost} / \text{Excessive weight} \times 100$

Terms

▣ Example:

- Initially a patient is 70 in. tall and 279 lbs (BMI = 40)
- He loses 52 lbs
- To have a BMI of 25 at 70 in, one must weigh 175 lbs.
- Excessive wgt = $279 - 175 = 104$
- $\%EWL = 52/104 \times 100 = 50\%$

Case

- ▣ A 30 year old woman is referred for obesity treatment after failing diet and lifestyle modification.
- ▣ Body Mass Index (BMI) 48.2
- ▣ 61 inches, 255 lbs

Bariatric surgery is the most effective weight loss intervention for the obese patient

Indications for Surgery (NIH)


- ▣ Be well informed and motivated
- ▣ BMI > 40 or
- ▣ BMI >35 with serious comorbidities (i.e. DM, OSA, obesity related cardiomyopathy, or severe DJD)
- ▣ Have acceptable risk of surgery
- ▣ Failed previous nonsurgical weight loss

Surgical Options

- ▣ Restrictive
 - Vertical banded gastroplasty (VBG)
 - Laparoscopic adjustable gastric band
 - Sleeve gastrectomy
- ▣ Malabsorptive
 - Jejunioileal bypass
 - Biliopancreatic diversion (BPD)
 - Biliopancreatic diversion with duodenal switch (BPD-DS)
- ▣ Combined restrictive and malabsorptive
 - Roux-en-Y gastric bypass

Surgery Works! SOS Trial

6328 patients




Surgery Works! SOS Trial

29% REDUCED RISK OF
DEATH

VBG

Complication rate requiring revision
20 – 56%.



- Staple line disruption
- Stoma stenosis
- Band erosion
- Band disruption
- Pouch dilation
- Vomiting
- GERD
- Poor results for “Sweet Tooth”


Lap Band

Lowest mortality rate among bariatric surgeries (< 0.5%)



- ▣ Acute stoma obstruction
- ▣ Infection
- ▣ Gastric perforation
- ▣ Hemorrhage
- ▣ Gastroparesis
- ▣ Band erosion, slippage, prolapse
- ▣ Port/tubing malfunction/leakage
- ▣ Pouch/esophageal dilation
- ▣ Esophagitis


Sleeve gastrectomy



- ❑ Better weight loss and hunger control than lap band
- ❑ Ghrelin suppression
- ❑ Leak
- ❑ Suture disruption
- ❑ Bleeding

Jejunioileal Bypass


One of the first bariatric operations



- ▣ Liver failure 30%
- ▣ Death
- ▣ Diarrhea
- ▣ Electrolyte imbalances
- ▣ Oxalate renal stones
- ▣ Vitamin deficiencies
- ▣ Malnutrition
- ▣ Arthritis


Biliopancreatic diversion

Introduced as a solution to high rates of liver failure with jejunoileal bypass



- ❑ Protein malabsorption
- ❑ Anemia
- ❑ Metabolic bone disease
- ❑ Vitamin Deficiencies
- ❑ Diarrhea
- ❑ Stoma ulcers


BPD - Duodenal Switch



- ▣ Partial sleeve gastrectomy
- ▣ Pylorus sparing
- ▣ Complex procedure
- ▣ Similar complications to BPD

Roux-en-Y Gastric Bypass

- ▣ Most common bariatric procedure performed in the U.S.



- ▣ PE/DVT
- ▣ Leaks up to 5%
- ▣ Bleeding
- ▣ Gastric remnant distension – rupture
- ▣ Infection
- ▣ Stoma stenosis
- ▣ Marginal Ulcers
- ▣ Gall stones
- ▣ Incisional/Internal hernias
- ▣ Dumping
- ▣ Vitamin/mineral deficiencies

Endoluminal Bariatric Procedures


- ▣ Compared to the laparoscopic bariatric surgery, the ideal endoluminal procedure would be:
 - Incisionless
 - Outpatient
 - Safer
 - Durable
 - More cost effective
 - Potentially offered to older, sicker patients, or those with milder obesity (BMI 30-35)

Endoluminal Obesity Options

- ▣ Intra gastric balloon
- ▣ Gastric Restriction
 - Endoluminal vertical gastroplasty (EndoCinch)
 - Transoral gastroplasty (TOGA)
- ▣ Duodenojejunal bypass sleeve

Intragastric Balloon


- ▣ One of the earliest endoluminal concepts to treat obesity
- ▣ Restrictive device
- ▣ Deployed into stomach under direct visualization
- ▣ Inflated with 500 to 700cc of saline/methylene blue



BioEnterics Intragastric Balloon (BIB)

Intragastric Balloon

- ▣ May be deflated and removed using a needle and snare or basket
- ▣ Complications include nausea, vomiting, erosion, ulceration, perforation, aspiration



Intragastric Balloon


- ▣ Retrospective analysis
- ▣ 2515 patients; mean BMI 44.8
- ▣ 2 unsuccessful placements (0.08%)
- ▣ 6-month follow-up %EWL 33.9 +/- 18.7
- ▣ Improvement/Resolution
 - DM – 86.9%
 - HTN – 93.7%
- ▣ Complications (2.8%)
 - 5 (0.19%) gastric perforations with 2 deaths

Intragastric Balloon

- ▣ 26 high risk “super-obese”
- ▣ Mean BMI 65.3 +/- 9.8
- ▣ At least 3 medical comorbidities
- ▣ Turned down for surgery with plans to undergo surgery as second stage
- ▣ 6-month follow up %EWL 22.4 +/- 14.5
- ▣ Improvement/resolution
 - DM – 81%
 - HTN – 83%
- ▣ Complication – 1 patient died within 24 hours from aspiration

Intragastric Balloon

- ▣ Often removed after 6 months
- ▣ Used successfully as a primer for more definitive bariatric surgery
- ▣ Not currently approved in the U.S.




Suturing/Stapling Devices


- ▣ Endoluminal Vertical Gastroplasty (EndoCinch)
- ▣ Transoral Gastroplasty (TOGA)

EndoCinch

- ▣ Initially for the treatment of GERD
 - Lacks durability
 - Often incomplete control of reflux

Endoluminal Vertical Gastroplasty (EndoCinch)





EndoCinch for Obesity

- ▣ 64 patients
- ▣ Seven sutures deployed from the proximal fundus to the distal body
- ▣ Procedure time 45 minutes
- ▣ %EWL
 - 1 month – 21.1%
 - 12 months – 58.1%

EndoCinch for Obesity


- ▣ 14 patients required repeat EGD within the first year
- ▣ 11 of those did NOT require repeat intervention
- ▣ Minimal complications
- ▣ Need long term outcomes

EndoCinch for Obesity


- ▣ Davol is initiating a randomized, multicenter trial in the U.S.


Transoral Gastroplasty (TOGA)


- ▣ www.satietyinc.com/toga-clinical-trial/overview/











TOGA

- ▣ Procedure time – 2 hours
- ▣ Transmural tissue apposition (?more durable)
- ▣ Sleeve length – 8cm from GEJ
- ▣ Luminal diameter of 20mm reduced to 12mm using the TOGA restrictor to pleat the gastric folds as needed

TOGA


- ▣ Feasibility trial, Belgium
- ▣ 11 patients
- ▣ Mean BMI > 41.6
- ▣ 9 patients had an intact staple line at discharge
- ▣ 7 intact at 6 months
- ▣ %EWL = 46.0% at 6 months (24 kg)
- ▣ No significant complications

TOGA

- ▣ Randomized, sham-controlled trial is ongoing in the U.S.

Duodenojejunal Bypass Sleeve (DJBS)

- ▣ First endoluminal device to bypass the proximal small bowel
- ▣ Self-expanding 60 cm plastic sleeve
- ▣ Wire-guided delivery under fluoroscopy
- ▣ Anchor is deployed into the duodenal bulb to hold the device in place



- ▣ www.gidynamics.com/delivery-method-endobarrier-gastrointestinal-liner



DJBS

- ▣ 12 patients
- ▣ Mean delivery time 26.6 minutes
- ▣ Sleeve remained in place in 10 patients for 12 weeks and was successfully removed
 - Mean removal time 43.3 min
 - 2 patients with refractory abdominal pain required early removal
- ▣ Mean %EWL 23.6 at 12 weeks
- ▣ Complications –
 - 1 minor oropharyngeal tear
 - 1 minor esophageal mucosal tear

DJBS

- ▣ 25 experimental patients vs. 14 controls
- ▣ 80% kept sleeve in place x 12 weeks
- ▣ %EWL – 22 (DJBS) vs. 5 (controls)
- ▣ Complications
 - 3 upper gi bleeds
 - 1 anchor migration
 - 1 stent obstruction

Case Resolution

- ▣ Pt underwent first TOGA procedure in U.S. at Washington University in St. Louis, MO
- ▣ http://daveproject.org/ViewFilms.cfm?Film_id=856

Summary

- ▣ Surgery is currently the best treatment for obesity, but it is not without complications
- ▣ Endoluminal approaches to obesity are being developed and may be available in the future